Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination

Kathleen Conroy, Susan L. Rosenthal, Gregory Zimet, Yan Jin, David I. Bernstein, Susan Glynn, Jessica A. Kahn

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

Objective: To describe human papillomavirus (HPV) vaccine uptake, predictors of vaccination, and barriers to vaccination in young women. Methods: Participants were 13-26-year-old girls and women recruited from an urban, hospital-based clinic. Between June and December 2007, 6 months after they had completed a baseline survey, they were recontacted to assess receipt of at least one HPV vaccine dose and barriers to receiving the vaccine. We assessed whether demographic factors, gynecological history, and attitudes measured at baseline were associated with vaccination at follow-up using logistic regression. Results: Of the 262 women who completed the baseline study, 189 (72%) participated in this follow-up study. At follow-up, 68 of 189 (36%) had received ≥1 HPV vaccine dose. Factors measured at baseline that predicted vaccination 6 months later included insurance coverage for HPV vaccination (odds ratio [OR] 5.31, 95% confidence interval [CI] 1.61-17.49) and the belief that one's parents, partners, and clinicians endorsed HPV vaccination (OR 2.21, 95% CI 1.29-3.79); those with a history of an abnormal Pap test were less likely to have received the vaccine (OR 0.30, CI 0.10-0.92). Of the 121 who were unvaccinated, 54 (45%) had not returned to the clinic since the baseline study, 51 (42%) had returned but were not offered vaccine, and 15 (12%) had declined vaccination. Conclusions: Interventions to increase HPV vaccination rates in women in the catch-up age group for vaccination should ensure that vaccine costs are covered, promote HPV vacci nation as normative, and establish clinic-based systems to prevent missed opportunities for vaccination.

Original languageEnglish
Pages (from-to)1679-1686
Number of pages8
JournalJournal of women's health (2002)
Volume18
Issue number10
DOIs
StatePublished - Oct 1 2009

Fingerprint

Papillomavirus Vaccines
Vaccination
Vaccines
Odds Ratio
Confidence Intervals
Papanicolaou Test
Insurance Coverage
Urban Hospitals
Age Groups
Parents
Logistic Models
History
Demography
Costs and Cost Analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. / Conroy, Kathleen; Rosenthal, Susan L.; Zimet, Gregory; Jin, Yan; Bernstein, David I.; Glynn, Susan; Kahn, Jessica A.

In: Journal of women's health (2002), Vol. 18, No. 10, 01.10.2009, p. 1679-1686.

Research output: Contribution to journalArticle

Conroy, Kathleen ; Rosenthal, Susan L. ; Zimet, Gregory ; Jin, Yan ; Bernstein, David I. ; Glynn, Susan ; Kahn, Jessica A. / Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. In: Journal of women's health (2002). 2009 ; Vol. 18, No. 10. pp. 1679-1686.
@article{4671b20cd149474dbaa370b4ea4adc17,
title = "Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination",
abstract = "Objective: To describe human papillomavirus (HPV) vaccine uptake, predictors of vaccination, and barriers to vaccination in young women. Methods: Participants were 13-26-year-old girls and women recruited from an urban, hospital-based clinic. Between June and December 2007, 6 months after they had completed a baseline survey, they were recontacted to assess receipt of at least one HPV vaccine dose and barriers to receiving the vaccine. We assessed whether demographic factors, gynecological history, and attitudes measured at baseline were associated with vaccination at follow-up using logistic regression. Results: Of the 262 women who completed the baseline study, 189 (72{\%}) participated in this follow-up study. At follow-up, 68 of 189 (36{\%}) had received ≥1 HPV vaccine dose. Factors measured at baseline that predicted vaccination 6 months later included insurance coverage for HPV vaccination (odds ratio [OR] 5.31, 95{\%} confidence interval [CI] 1.61-17.49) and the belief that one's parents, partners, and clinicians endorsed HPV vaccination (OR 2.21, 95{\%} CI 1.29-3.79); those with a history of an abnormal Pap test were less likely to have received the vaccine (OR 0.30, CI 0.10-0.92). Of the 121 who were unvaccinated, 54 (45{\%}) had not returned to the clinic since the baseline study, 51 (42{\%}) had returned but were not offered vaccine, and 15 (12{\%}) had declined vaccination. Conclusions: Interventions to increase HPV vaccination rates in women in the catch-up age group for vaccination should ensure that vaccine costs are covered, promote HPV vacci nation as normative, and establish clinic-based systems to prevent missed opportunities for vaccination.",
author = "Kathleen Conroy and Rosenthal, {Susan L.} and Gregory Zimet and Yan Jin and Bernstein, {David I.} and Susan Glynn and Kahn, {Jessica A.}",
year = "2009",
month = "10",
day = "1",
doi = "10.1089/jwh.2008.1329",
language = "English",
volume = "18",
pages = "1679--1686",
journal = "Journal of Women's Health",
issn = "1540-9996",
publisher = "Mary Ann Liebert Inc.",
number = "10",

}

TY - JOUR

T1 - Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination

AU - Conroy, Kathleen

AU - Rosenthal, Susan L.

AU - Zimet, Gregory

AU - Jin, Yan

AU - Bernstein, David I.

AU - Glynn, Susan

AU - Kahn, Jessica A.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Objective: To describe human papillomavirus (HPV) vaccine uptake, predictors of vaccination, and barriers to vaccination in young women. Methods: Participants were 13-26-year-old girls and women recruited from an urban, hospital-based clinic. Between June and December 2007, 6 months after they had completed a baseline survey, they were recontacted to assess receipt of at least one HPV vaccine dose and barriers to receiving the vaccine. We assessed whether demographic factors, gynecological history, and attitudes measured at baseline were associated with vaccination at follow-up using logistic regression. Results: Of the 262 women who completed the baseline study, 189 (72%) participated in this follow-up study. At follow-up, 68 of 189 (36%) had received ≥1 HPV vaccine dose. Factors measured at baseline that predicted vaccination 6 months later included insurance coverage for HPV vaccination (odds ratio [OR] 5.31, 95% confidence interval [CI] 1.61-17.49) and the belief that one's parents, partners, and clinicians endorsed HPV vaccination (OR 2.21, 95% CI 1.29-3.79); those with a history of an abnormal Pap test were less likely to have received the vaccine (OR 0.30, CI 0.10-0.92). Of the 121 who were unvaccinated, 54 (45%) had not returned to the clinic since the baseline study, 51 (42%) had returned but were not offered vaccine, and 15 (12%) had declined vaccination. Conclusions: Interventions to increase HPV vaccination rates in women in the catch-up age group for vaccination should ensure that vaccine costs are covered, promote HPV vacci nation as normative, and establish clinic-based systems to prevent missed opportunities for vaccination.

AB - Objective: To describe human papillomavirus (HPV) vaccine uptake, predictors of vaccination, and barriers to vaccination in young women. Methods: Participants were 13-26-year-old girls and women recruited from an urban, hospital-based clinic. Between June and December 2007, 6 months after they had completed a baseline survey, they were recontacted to assess receipt of at least one HPV vaccine dose and barriers to receiving the vaccine. We assessed whether demographic factors, gynecological history, and attitudes measured at baseline were associated with vaccination at follow-up using logistic regression. Results: Of the 262 women who completed the baseline study, 189 (72%) participated in this follow-up study. At follow-up, 68 of 189 (36%) had received ≥1 HPV vaccine dose. Factors measured at baseline that predicted vaccination 6 months later included insurance coverage for HPV vaccination (odds ratio [OR] 5.31, 95% confidence interval [CI] 1.61-17.49) and the belief that one's parents, partners, and clinicians endorsed HPV vaccination (OR 2.21, 95% CI 1.29-3.79); those with a history of an abnormal Pap test were less likely to have received the vaccine (OR 0.30, CI 0.10-0.92). Of the 121 who were unvaccinated, 54 (45%) had not returned to the clinic since the baseline study, 51 (42%) had returned but were not offered vaccine, and 15 (12%) had declined vaccination. Conclusions: Interventions to increase HPV vaccination rates in women in the catch-up age group for vaccination should ensure that vaccine costs are covered, promote HPV vacci nation as normative, and establish clinic-based systems to prevent missed opportunities for vaccination.

UR - http://www.scopus.com/inward/record.url?scp=70350455774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350455774&partnerID=8YFLogxK

U2 - 10.1089/jwh.2008.1329

DO - 10.1089/jwh.2008.1329

M3 - Article

C2 - 19785564

AN - SCOPUS:70350455774

VL - 18

SP - 1679

EP - 1686

JO - Journal of Women's Health

JF - Journal of Women's Health

SN - 1540-9996

IS - 10

ER -